A smaller subset of genetically stable OSCCs (GS-OSCC) with a better prognosis has been identified; these tumours contain wild-type p53, are CNA-silent and often contain oncogenic HRAS mutations and inactivation of CASP84–6. Here, TP53 is linked to neoplasm.